Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
P.VillaltaF.et al
The final indication will follow once the medicine is approved
In the latest phase 3 trial of orforglipron, three doses of the drug were compared with a placebo in 1,613 people with type 2 diabetes who were overweight or had obesity
Retrieved from Polycystic Ovary Syndrome (PCOS) Springer Healthcare
a full glass of water usually smooths it out
The most clearly defined groups who may be considered in future include individuals with: Metabolic dysfunction-associated steatotic liver disease (MASLD) particularly those with concurrent obesity, type 2 diabetes, or metabolic syndrome Metabolic dysfunction-associated steatohepatitis (MASH) the progressive inflammatory subtype associated with fibrosis and risk of cirrhosis Obesity with elevated liver enzymes (ALT/AST) where hepatic steatosis has been confirmed on imaging Type 2 diabetes with evidence of hepatic fat accumulation , where current glucose-lowering therapies have not adequately addressed liver disease Patients with significant hepatic fibrosis (stage F2 or above) represent a group with particularly high unmet need, as there are currently no licensed pharmacological treatments specifically approved for MASH in the UK
US$ 27.05
US$ 22.29
US$ 27.95
